Comparison of the efficacy of pre-transplant and post-transplant antithymocyte globulin combined with post-transplant cyclophosphamide for graft- versus -host disease prophylaxis in myeloablative haploidentical peripheral blood stem cell transplantation
Cell Transplantation · 2026-06 · 35
DOI: 10.1177/09636897261454024 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cell Transplantation, online erschienen am 01.06.2026. Verfasst von Xuelian Jin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Graft vs Host Disease, Cyclophosphamide, Antilymphocyte Serum, Peripheral Blood Stem Cell Transplantation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Clinical Research Incubation Project, West China Hospital, Sichuan University.
Abstract (Originalsprache)
Although post-transplant cyclophosphamide (PTCy) is widely used to prevent graft-versus-host disease (GVHD), its protective effect remains inadequate in patients undergoing myeloablative haploidentical peripheral blood stem cell transplantation (haplo-PBSCT). We retrospectively evaluated the efficacy of PTCy combined with either pre-transplant or post-transplant antithymocyte globulin (ATG) for GVHD prevention in 114 haplo-PBSCT recipients. The PTCy+FTATG group (n = 74) received ATG at a total dose of 5 mg/kg on days −3 to −1, together with PTCy at 25 mg/kg on days +3 and +4. The PTCy+PTATG group (n = 40) received PTCy at 50 mg/kg on days +3 and +4, followed by ATG at 2.5 mg/kg on day +8. Both univariate and multivariate analyses showed that PTCy+FTATG prophylaxis significantly lowered the risk of grade II–IV acute GVHD (9.5% vs 27.5% [HR 0.24; 95% CI: 0.10–0.59; P = 0.002]) and grade III–IV acute GVHD (5.4% vs 17.5% [HR 0.19; 95% CI: 0.07–0.54; P = 0.002]). The 2-year cumulative incidence of chronic GVHD was 16.7% in the PTCy+FTATG group and 27.5% in the PTCy+PTATG group ( P = 0.15). At 2 years, overall survival (OS), progression-free survival (PFS), and graft-versus-host disease-free relapse-free survival (GRFS) were 87.8% vs 72.5% ( P = 0.04), 82.2% vs 65.0% ( P = 0.03), and 78.1% vs 55.0% ( P = 0.005), respectively. These results suggest that half-dose PTCy combined with low-dose pre-transplant ATG may be a promising strategy for GVHD prophylaxis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Xinchuan Chen
Förderung
- Clinical Research Incubation Project
- West China Hospital, Sichuan University
Zitieren
APA
Jin, X., Dong, T., Ji, J., Liu, Z., Kuang, P., Li, J., Wu, Y., Xu, J., Wang, Z., Zeng, J., Xiong, Z., & Chen, X. (2026). Comparison of the efficacy of pre-transplant and post-transplant antithymocyte globulin combined with post-transplant cyclophosphamide for graft- versus -host disease prophylaxis in myeloablative haploidentical peripheral blood stem cell transplantation. Cell Transplantation, 35. https://doi.org/10.1177/09636897261454024
Vancouver
Jin X, Dong T, Ji J, Liu Z, Kuang P, Li J, et al. Comparison of the efficacy of pre-transplant and post-transplant antithymocyte globulin combined with post-transplant cyclophosphamide for graft- versus -host disease prophylaxis in myeloablative haploidentical peripheral blood stem cell transplantation. Cell Transplantation. 2026;35. doi:10.1177/09636897261454024
BibTeX
@article{Jin2026,
author = {Jin, Xuelian and Dong, Tian and Ji, Jie and Liu, Zhigang and Kuang, Pu and Li, Jian and Wu, Yu and Xu, Juan and Wang, Zerong and Zeng, Jiajia and Xiong, Zilin and Chen, Xinchuan},
title = {Comparison of the efficacy of pre-transplant and post-transplant antithymocyte globulin combined with post-transplant cyclophosphamide for graft- versus -host disease prophylaxis in myeloablative haploidentical peripheral blood stem cell transplantation},
journal = {Cell Transplantation},
year = {2026},
volume = {35},
doi = {10.1177/09636897261454024}
}
EUVIMED